TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30782698
Drug: Liposomal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal lidocaine 4% cream (topical anaesthetic)
Study: 30782749
Drug: Weekly emails
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly emails and monthly phone calls for 3 months
Study: 30782924
Drug: Hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital treatment for non-complex fractures or dislocations
Study: 30782999
Drug: Levofloxacin (750-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (750- to 1,000-mg once-daily dosing)
Study: 30783204
Drug: Eribulin mesilate
Normalized name: Eribulin mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin mesilate (1.6 mg/m²) in combination with capecitabine (1000 mg/m² twice daily)
Study: 30785829
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus low-dose ipilimumab (nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks)
Study: 30786188
Drug: Sacituzumab govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan-hziy (10 mg/kg) administered intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects.
Study: 30787085
Drug: Patient Information
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient Information Leaflets (PILs) given by physicians along with an oral explanation.
Study: 30787176
Drug: TAS0728, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS0728, a covalent-binding HER2-selective kinase inhibitor
Study: 30787641
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50,000 IU weekly)
Study: 30787641
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (300 mg daily)
Study: 30787641
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Vitamin D3 and Omega-3 fatty acids
Study: 30788134
Drug: Pharmacist-administered HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-administered HIV point-of-care testing (POCT) with pre/post-test counseling and linkage to care plans
Study: 30788134
Drug: Pharmacist-administered HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-administered HIV point-of-care testing (POCT)
Study: 30789827
Drug: 12-week intensive
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week intensive outpatient rehabilitation including memantine and morphine treatment, psychological and physiotherapeutic intervention
Study: 30790469
Drug: Palliative gastric
Normalized name: gastric mucins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palliative gastric radiotherapy (36 Gy in 12 daily fractions)
Study: 30792190
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg orally twice daily, pomalidomide 4 mg orally on days 1 to 21, and dexamethasone 40 mg orally on days 1, 8, 15, and 22 of a 28-day cycle
Study: 30793701
Drug: Drugs associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs associated with drug-induced lupus (DIL)
Study: 30794033
Drug: Induced subgroups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induced subgroups from empirical data on treatment effectiveness
Study: 30795996
Drug: Daratumumab (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab (16 mg/kg; administered intravenously weekly for 2 cycles, every 2 weeks for 4 cycles, and every 4 weeks thereafter)
Study: 30796032
Drug: MTI-31 (LXI-15029),
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTI-31 (LXI-15029), a novel mTORC1/mTORC2 inhibitor
Study: 30796035
Drug: ADI-PEG20 (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADI-PEG20 (36 mg/m weekly) with pemetrexed and cisplatin (ADIPEMCIS)
Study: 30796155
Drug: Genexol-PM (230
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genexol-PM (230 mg/m2) plus cisplatin
Study: 30796821
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment (pertuzumab, trastuzumab, and taxane)
Study: 30796821
Drug: Docetaxel-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel-containing therapy
Study: 30796821
Drug: Paclitaxel-containing therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel-containing therapy
Study: 30797139
Drug: Bendamustine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendamustine and rituximab (BR) as first-line treatment
Study: 30797575
Drug: Opioid prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid prescription and pain management
Study: 30797634
Drug: ACE527 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE527 vaccine with dmLT adjuvant
Study: 30797634
Drug: ACE527 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE527 vaccine without adjuvant
Study: 30797636
Drug: Pneumococcal polysaccharide-based
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide-based vaccines (PPV and/or PCV/PPV)
Study: 30800421
Drug: ABX464 150-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 150-mg
Study: 30800421
Drug: ABX464 50-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABX464 50-mg
Study: 30800562
Drug: Ipragliflozin 50
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 50 mg once-daily
Study: 30800562
Drug: Ipragliflozin with
Normalized name: bexagliflozin
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin with DPP-4 inhibitor
Study: 30801647
Drug: Tomato-soy juice
Normalized name: tomato juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tomato-soy juice (0, 1, or 2 cans/day; 163 mL/can; 20.6 mg lycopene, 1.2 mg β-carotene/can) for 24 ± 0.7 days
Study: 30801984
Drug: Total Daily
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Daily Energy Expenditure (TDEE) in WLM
Study: 30801989
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary self-monitoring using a Web-based dietary analysis program
Study: 30802998
Drug: VY-AADC01 (8.3 × 10^10
Approvals — FDA: no, EMA: no, PMDA: no
Description: VY-AADC01 (8.3 × 10^10 vg/mL) administered bilaterally with gadoteridol using MRI guidance
Study: 30803705
Drug: Miransertib at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miransertib at a dose of 5 mg/m
Study: 30803990
Drug: Parsaclisib monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parsaclisib monotherapy (5-45 mg once daily)
Study: 30803997
Drug: Non-drug interventions
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-drug interventions for perinatal depression
Study: 30803997
Drug: Personalized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized treatment approaches
Study: 30803997
Drug: Novel treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel treatments under investigation
Study: 30804020
Drug: Chimeric HER-2
Normalized name: HER-2/neu inhibitor
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric HER-2 B-cell peptide vaccines emulsified in Montanide ISA 720VG and Nor-MDP adjuvant, administered as three inoculations every 3 weeks.
Study: 30805946
Drug: Methadone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone (single oral dose)
Study: 30805946
Drug: Simplified dosing
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simplified dosing strategy (model-based simulations)
Study: 30808583
Drug: Afatinib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib (40 mg/d) with Pembrolizumab (200 mg every 3 weeks)
Study: 30809591
Drug: Intrathecal tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal tetanus antitoxin and human intramuscular treatment
Study: 30809591
Drug: Intrathecal tetanus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal tetanus antitoxin and equine intramuscular treatment
Study: 30809591
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure and human intramuscular treatment
Study: 30809591
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure and equine intramuscular treatment
Study: 30810343
Drug: Pre-treatment PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment PET parameters (FDG-PET/CT)
Study: 30810343
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HPV with PET parameters (MTV, TLG, ZMP)
Study: 30810343
Drug: PET 2
Normalized name: benzocain-camphor-allatoin-pet 20 %-3 %-1 %-64.9 % TOPICAL OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET 2 weeks into treatment
Study: 30810343
Drug: Pre-treatment PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment PET parameters
Study: 30810343
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in PET parameters from pre- to mid-treatment
Study: 30811142
Drug: Tavaborole 5%
Normalized name: TAVABOROLE 5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tavaborole 5% topical solution applied once daily to all affected toenails for 48 weeks
Study: 30811142
Drug: Tavaborole 5%
Normalized name: TAVABOROLE 5% SOLN,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tavaborole 5% topical solution applied for the first 28 days to all 10 toenails and ≤2 mm of surrounding skin in a maximal-use subgroup (aged 12 to <17 years)
Study: 30811285
Drug: Hu5F9-G4 (5F9)
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu5F9-G4 (5F9) antibody at a priming dose of 1 mg/kg followed by maintenance doses of 3 to 45 mg/kg weekly
Study: 30811537
Drug: Asfotase alfa
Normalized name: Asfotase alfa
DrugBank: Asfotase alfa (DB09105)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Asfotase alfa 2 mg/kg three times/week or 1 mg/kg six times/week subcutaneously
Study: 30814321
Drug: Candesartan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (16 mg) plus hydrochlorothiazide (12.5 mg)
Study: 30814321
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Candesartan plus Hydrochlorothiazide and Rosuvastatin)
Study: 30815467
Drug: Blood and
Normalized name: BLOOD AND RELATED PRODUCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood and sputum sampling monthly and at exacerbation to detect respiratory infections and eosinophilic inflammation
Study: 30815468
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and one or more bronchodilators prior to study entry
Study: 30816809
Drug: Real-world therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-world therapies chosen for multiple myeloma patients
Study: 30819210
Drug: Sotagliflozin (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin (as monotherapy or add-on therapy)
Study: 30819210
Drug: Sotagliflozin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotagliflozin (in adults with T1D treated with continuous subcutaneous insulin infusion or multiple daily insulin injections)
Study: 30819913
Drug: Platelet transfusions
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet transfusions at a threshold platelet count of 50x10^9/L
Study: 30821848
Drug: ipilimumab treatment
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: ipilimumab treatment
Study: 30822272
Drug: sitagliptin 100
Normalized name: SITagliptin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin 100 mg, once daily
Study: 30822272
Drug: vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: vildagliptin 50 mg, twice daily
Study: 30822272
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg, once daily
Study: 30822389
Drug: Lumbar stabilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar stabilization exercise program (twice a week for 8 weeks)
Study: 30825104
Drug: Pexidartinib 600
Normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pexidartinib 600 mg/d
Study: 30825104
Drug: Pexidartinib 1000
Normalized name: PEXIDARTINIB
DrugBank: Pexidartinib (DB12978)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pexidartinib 1000 mg/d for 2 weeks, then 800 mg/d thereafter
Study: 30825970
Drug: Concurrent SBRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent SBRT (40 Gy) and nelfinavir (1250 mg BID for 5 weeks)
Study: 30826528
Drug: Admission cTnI
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Admission cTnI > 0.46 ng/mL with STEMI present in ECG
Study: 30832606
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg administered every 2 weeks up to 24 months or until confirmed progression or intolerable toxicity
Study: 30832636
Drug: Persona Knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persona Knee Implant System
Study: 30832732
Drug: α-PD-1 therapy
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-PD-1 therapy
Study: 30832732
Drug: α-TGFβ monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-TGFβ monotherapy
Study: 30832732
Drug: α-PD-1 and
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-PD-1 and α-TGFβ combinatorial therapy
Study: 30832732
Drug: α-TGFβ antibody
Normalized name: digoxin antibodies Fab fragments
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-TGFβ antibody administration
Study: 30833313
Drug: Biomarkers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarkers of interest focusing on metabolism (lipids, amino acids) and inflammation (adipokines, cytokines, and chemokines).
Study: 30833442
Drug: Carboplatin treatment
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin treatment with hypersensitivity reaction management
Study: 30833489
Drug: Merestinib (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merestinib (120 mg once daily)
Study: 30834280
Drug: Nutritional supplement
Normalized name: Nutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplement (Progen) containing hydrolyzed collagen peptides, plasma proteins, hyaluronic acid-chondroitin sulfate complex, and vitamin C
Study: 30834940
Drug: sunitinib 37.5
Normalized name: sunitinib 37.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sunitinib 37.5 mg/day on a continuous daily dosing schedule
Study: 30835255
Drug: De novo
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De novo synthesized neoantigen-loaded dendritic cell vaccines
Study: 30835255
Drug: Personalized immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized immunotherapy
Study: 30836948
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium concentration > 2.5 mEq/L
Study: 30836948
Drug: Intravenous potassium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous potassium and weight change
Study: 30839493
Drug: Systemic hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic hormone therapy (HT) prescriptions
Study: 30839493
Drug: New prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: New prescriptions for systemic HT
Study: 30839493
Drug: Renewal prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renewal prescriptions for systemic HT
Study: 30839493
Drug: Renewal prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renewal prescriptions with conjugated equine estrogen doses ≥0.625 mg
Study: 30839493
Drug: Prescriptions for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions for systemic estrogen in women with a uterus
Study: 30840757
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment (4000 units daily for 2 weeks)
Study: 30840787
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg) for 8 weeks (Phase 1)
Study: 30840787
Drug: Escitalopram (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (10-20 mg) continued for responders, adjunctive aripiprazole (2-10 mg) for nonresponders for a further 8 weeks (Phase 2)
Study: 30843107
Drug: Increased salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased salt iodine concentration from 20 to 25 mg/kg
Study: 30843107
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previous iodine concentration of 20 mg/kg)
Study: 30843659
Drug: Ruxolitinib (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (5, 10, 15, or 20 mg BID for 3 weeks out of five for seven cycles) combined with Ibrutinib (420 mg daily)
Study: 30845873
Drug: Low- or
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low- or high-dose β-blockers
Study: 30845997
Drug: Three servings
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three servings (28.3 g each) of sun dried raisins daily for 14 days
Study: 30846500
Drug: Weekly subcutaneous
Normalized name: Weekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×10^9/L)
Study: 30848695
Drug: Ciprofloxacin Dry
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin Dry Powder for Inhalation
Study: 30849082
Drug: 5-hour oral
Normalized name: 3α-(diphenylmethoxy)-1αH,5αH-tropane
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hour oral glucose tolerance test to measure DI by OMM
Study: 30850297
Drug: Endurant II/IIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endurant II/IIs endograft in conjunction with Heli-FX EndoAnchor implants (ESAR)
Study: 30850381
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus G-CHOP
Study: 30850381
Drug: G-CHOP (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CHOP (control)
Study: 30850562
Drug: Endostatin and
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endostatin and oxaliplatin (OHP) administered intravenously at doses of 7.5 mg/m², with radiotherapy delivered at a daily fraction of 2.0 Gy to a total dose of 60.0 Gy over 6 weeks.
Study: 30852126
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 3.73 ± 1.72 mg) for 6 weeks
Study: 30852546
Drug: Volatile organic
Normalized name: coal tar pitch volatiles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volatile organic compounds (VOCs) evaluation using offline and online technologies including proton transfer reaction mass spectrometry, gas chromatography ion mobility spectrometry, atmospheric pressure chemical ionisation-mass spectrometry, gas chromatography mass spectroscopy, and comprehensive two-dimensional gas chromatography-mass spectrometry.
Study: 30854456
Drug: Spectroscopic MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectroscopic MRI (sMRI) integrated with standard imaging for radiation therapy planning
Study: 30857532
Drug: Post-procedural glycemic
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-procedural glycemic variability (mean daily δ blood glucose during the first 2 days after TAVI, median value 4.3 mmol/l)
Study: 30857780
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with a different antiviral regimen
Study: 30857956
Drug: Pertuzumab (840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab (840 mg loading dose, then 420 mg every 3 weeks, intravenously) and trastuzumab (8 mg/kg loading dose, then 6 mg/kg every 3 weeks, intravenously)
Study: 30858218
Drug: DSM265 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM265 at 400 mg
Study: 30858985
Drug: Fish protein
Normalized name: Fish Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish protein supplementation (5.2 g daily for 6 weeks)
Study: 30859424
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent blue dye injection
Study: 30859504
Drug: Personalized trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized trials of BP medications
Study: 30859504
Drug: Renin-angiotensin system-blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin system-blocking agents
Study: 30859504
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of thiazide and beta-blocker